首页 > 最新文献

Infectious disorders drug targets最新文献

英文 中文
Discharge of Confirmed COVID-19 Patients Based on WHO or Regional Criteria? A Cohort Study. COVID-19确诊患者出院是基于世卫组织标准还是区域标准?一项队列研究。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220815151958
Seyed-Hasan Adeli, Mahmoud Parham, Akram Asghari, Mohammad Bagherzade, Rasoul Shajari, Reihane Tabarraii, Masoumeh Shakeri, Amir Jabbari, Saeede Jafari, Sajjad Ahmadpour, Mohammad Amin Habibi, Javad Khodadai, Hamed Shafiee, Narges Eskandari, Davoud Olad Dameshghi, Maryam Masoumi, Seyed Yaser Foroghi Ghomi, Ali Ebrazeh, Jamshid Vafaeimanesh

Background: Increasing the number of COVID-19 patients raises concerns about the capacity of the health care system. This issue emphasizes reducing the admission rate and expediting patient discharge.

Objective: This study aimed to develop a discharge protocol for COVID-19 patients based on the existing capacity of the healthcare system and to assess its post-discharge outcomes.

Methods: This is a multicenter cohort study. All COVID-19 patients referred to selected medical centers in Qom, Iran, from Feb. 19 to Apr. 19, 2020, were target populations. Eligible patients were classified into a) the criterion group and b) the non-criterion group. Patients were followed up daily for 14 days after discharge by phone, and the required data was gathered and recorded in follow-up form. Univariate (chi-square and t-tests) and multivariate multiple (multivariate probit regression) analysis were used.

Results: A total of 2775 patients were included in the study (1440 people in the criterion group and 1335 in the non-criterion group). Based on multivariate probit regression, death was statistically associated with discharge outside our criteria (p<0.001), rising age (p<0.001), and being male (p=0.019), and readmission were associated with discharge outside our criteria (p<0.001), rising age (p=0.009), and having the history of underlying diseases (p=0.003). Furthermore, remission had statistically significant associations with discharge based on our criteria (p<0.001), decreasing age (p=0.001), and lack of a history of underlying diseases (p<0.001).

Conclusion: Mortality and readmission were significantly lower according to our discharge criteria. Our designed criteria apply to less developed and developing countries due to the limited capacity and resources available in the health care system.

背景:COVID-19患者人数的增加引发了人们对卫生保健系统能力的担忧。这个问题强调降低住院率和加快病人出院。目的:本研究旨在根据现有医疗系统的能力制定COVID-19患者的出院方案,并评估其出院后结果。方法:这是一项多中心队列研究。2020年2月19日至4月19日在伊朗库姆选定的医疗中心转诊的所有COVID-19患者都是目标人群。将符合条件的患者分为a)标准组和b)非标准组。出院后,每天对患者进行14天的电话随访,收集所需资料并记录在随访表中。采用单因素(卡方检验和t检验)和多因素(多因素probit回归)分析。结果:共纳入2775例患者(标准组1440例,非标准组1335例)。基于多变量概率回归,死亡与超出我们标准的出院有统计学关联(结论:根据我们的出院标准,死亡率和再入院率显著降低。由于卫生保健系统的能力和资源有限,我们设计的标准适用于欠发达国家和发展中国家。
{"title":"Discharge of Confirmed COVID-19 Patients Based on WHO or Regional Criteria? A Cohort Study.","authors":"Seyed-Hasan Adeli,&nbsp;Mahmoud Parham,&nbsp;Akram Asghari,&nbsp;Mohammad Bagherzade,&nbsp;Rasoul Shajari,&nbsp;Reihane Tabarraii,&nbsp;Masoumeh Shakeri,&nbsp;Amir Jabbari,&nbsp;Saeede Jafari,&nbsp;Sajjad Ahmadpour,&nbsp;Mohammad Amin Habibi,&nbsp;Javad Khodadai,&nbsp;Hamed Shafiee,&nbsp;Narges Eskandari,&nbsp;Davoud Olad Dameshghi,&nbsp;Maryam Masoumi,&nbsp;Seyed Yaser Foroghi Ghomi,&nbsp;Ali Ebrazeh,&nbsp;Jamshid Vafaeimanesh","doi":"10.2174/1871526522666220815151958","DOIUrl":"https://doi.org/10.2174/1871526522666220815151958","url":null,"abstract":"<p><strong>Background: </strong>Increasing the number of COVID-19 patients raises concerns about the capacity of the health care system. This issue emphasizes reducing the admission rate and expediting patient discharge.</p><p><strong>Objective: </strong>This study aimed to develop a discharge protocol for COVID-19 patients based on the existing capacity of the healthcare system and to assess its post-discharge outcomes.</p><p><strong>Methods: </strong>This is a multicenter cohort study. All COVID-19 patients referred to selected medical centers in Qom, Iran, from Feb. 19 to Apr. 19, 2020, were target populations. Eligible patients were classified into a) the criterion group and b) the non-criterion group. Patients were followed up daily for 14 days after discharge by phone, and the required data was gathered and recorded in follow-up form. Univariate (chi-square and t-tests) and multivariate multiple (multivariate probit regression) analysis were used.</p><p><strong>Results: </strong>A total of 2775 patients were included in the study (1440 people in the criterion group and 1335 in the non-criterion group). Based on multivariate probit regression, death was statistically associated with discharge outside our criteria (p<0.001), rising age (p<0.001), and being male (p=0.019), and readmission were associated with discharge outside our criteria (p<0.001), rising age (p=0.009), and having the history of underlying diseases (p=0.003). Furthermore, remission had statistically significant associations with discharge based on our criteria (p<0.001), decreasing age (p=0.001), and lack of a history of underlying diseases (p<0.001).</p><p><strong>Conclusion: </strong>Mortality and readmission were significantly lower according to our discharge criteria. Our designed criteria apply to less developed and developing countries due to the limited capacity and resources available in the health care system.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 1","pages":"e150822207493"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10668891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential of Black Seeds (Nigella sativa) in the Management of Long COVID or Post-acute Sequelae of COVID-19 (PASC) and Persistent COVID-19 Symptoms - An Insight. 黑籽(Nigella sativa)治疗COVID-19长期或急性后后遗症(PASC)和持续COVID-19症状的潜力
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230223112045
Naina Mohamed Pakkir Maideen, Abdurazak Hassan Jumale, Ibrahim Ramadan Barakat, Ayesha Khalifa Albasti

Background: Some individuals may experience symptoms persisting for many months after the recovery from COVID-19 and patients with Long COVID are managed mainly with symptomatic treatment and supportive care.

Objective: This review article focuses on the beneficial effects of black seeds (Nigella sativa) in the management of long COVID and persistent COVID symptoms.

Methods: The literature was searched in databases such as LitCOVID, Web of Science, Google Scholar, bioRxiv, medRxiv, Science Direct, EBSCO, Scopus, Embase, and reference lists to identify studies, which evaluated various effects of black seeds (N. sativa) related to signs and symptoms of long COVID.

Results: Black seeds (N. sativa) have shown potential anti-COVID, antiviral, anti-inflammatory, antioxidant, immunomodulatory, antihypertensive, anti-obesity, antidiabetic, antihyperlipidemic, and antiasthmatic properties in various clinical, animal, in vitro, in vivo, and in silico studies, which would help the patients recovered from COVID to mitigate Long COVID complications.

Conclusion: Patients experiencing Long COVID may use black seeds (N. sativa) as adjunctive therapy in combination with symptomatic treatment and supportive care to prevent further deterioration and hospitalization. The safety and efficacy of N. sativa in patients with Long-COVID would further be established by future randomized controlled clinical trials.

背景:一些个体在COVID-19康复后可能会出现持续数月的症状,长期COVID-19患者主要通过对症治疗和支持性护理进行管理。目的:综述黑籽(Nigella sativa)在治疗长时间COVID和持续性COVID症状中的有益作用。方法:在LitCOVID、Web of Science、Google Scholar、bioRxiv、medRxiv、Science Direct、EBSCO、Scopus、Embase等数据库和参考文献列表中检索文献,评价黑籽(N. sativa)对长冠状病毒体征和症状的各种影响。结果:黑籽(N. sativa)在各种临床、动物、体外、体内和计算机研究中显示出潜在的抗COVID、抗病毒、抗炎、抗氧化、免疫调节、降压、抗肥胖、降糖、降血脂和平喘气的特性,有助于患者从COVID中恢复,减轻长期COVID并发症。结论:长冠患者可将黑籽(N. sativa)作为辅助治疗,结合对症治疗和支持护理,防止病情进一步恶化和住院治疗。sativa在Long-COVID患者中的安全性和有效性将通过未来的随机对照临床试验进一步确定。
{"title":"Potential of Black Seeds (<i>Nigella sativa</i>) in the Management of Long COVID or Post-acute Sequelae of COVID-19 (PASC) and Persistent COVID-19 Symptoms - An Insight.","authors":"Naina Mohamed Pakkir Maideen,&nbsp;Abdurazak Hassan Jumale,&nbsp;Ibrahim Ramadan Barakat,&nbsp;Ayesha Khalifa Albasti","doi":"10.2174/1871526523666230223112045","DOIUrl":"https://doi.org/10.2174/1871526523666230223112045","url":null,"abstract":"<p><strong>Background: </strong>Some individuals may experience symptoms persisting for many months after the recovery from COVID-19 and patients with Long COVID are managed mainly with symptomatic treatment and supportive care.</p><p><strong>Objective: </strong>This review article focuses on the beneficial effects of black seeds (Nigella sativa) in the management of long COVID and persistent COVID symptoms.</p><p><strong>Methods: </strong>The literature was searched in databases such as LitCOVID, Web of Science, Google Scholar, bioRxiv, medRxiv, Science Direct, EBSCO, Scopus, Embase, and reference lists to identify studies, which evaluated various effects of black seeds (N. sativa) related to signs and symptoms of long COVID.</p><p><strong>Results: </strong>Black seeds (N. sativa) have shown potential anti-COVID, antiviral, anti-inflammatory, antioxidant, immunomodulatory, antihypertensive, anti-obesity, antidiabetic, antihyperlipidemic, and antiasthmatic properties in various clinical, animal, in vitro, in vivo, and in silico studies, which would help the patients recovered from COVID to mitigate Long COVID complications.</p><p><strong>Conclusion: </strong>Patients experiencing Long COVID may use black seeds (N. sativa) as adjunctive therapy in combination with symptomatic treatment and supportive care to prevent further deterioration and hospitalization. The safety and efficacy of N. sativa in patients with Long-COVID would further be established by future randomized controlled clinical trials.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 4","pages":"e230223213955"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9788844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Marburg Virus- A Threat During SARS-CoV-2 Era: A Review. 马尔堡病毒——SARS-CoV-2时代的威胁:综述
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230228103845
Sumel Ashique, Vatan Chaudhary, Soumen Pal, Jonee Panwar, Mukesh Kumar, Soumi Pramanik, Abhipsa Sinha, Anagh Mukherjee

In the German towns of Marburg, Frankfurt, and Belgrade in 1967, this single negativestranded RNA virus was initially discovered. The importation of infected grivet monkeys from Uganda is what caused this virus-related sickness. As a result of the early link between viruses and non-human primates, this virus is frequently referred to as vervet monkey sickness. This virus causes Marburg hemorrhagic fever in humans and non-human primates. Human endothelial cells serve as the primary vehicle for replication. According to a 2009 report, the virus was being stored in Egyptian fruit bats (Rousettus aegyptiacus). Body fluids, unprotected sex, broken or injured skin, and other bodily fluids are the main routes of transmission. After the incubation period, symptoms like chills, headaches, myalgia, and stomach pain start to show up. There is no specific medication for such an infection, only hydration therapy and adequate oxygenation are followed. The following diagnostic techniques can be used to confirm the diagnosis: (i) an antibody-capture enzyme linked immunosorbent assay (ELISA); ii) an antigen capture ELISA test; iii) a serum neutralization test; iv) an RT PCR assay; v) electron microscopy; or vi) virus isolation by cell culture. Because MARV is a risk group 4 infection, laboratory staff must take strict precautions (RG-4).

1967年,在德国的马尔堡、法兰克福和贝尔格莱德,这种单负链RNA病毒最初被发现。从乌干达输入受感染的灰猴是导致这种病毒相关疾病的原因。由于病毒与非人类灵长类动物之间的早期联系,这种病毒通常被称为长尾猴病。这种病毒在人类和非人类灵长类动物中引起马尔堡出血热。人内皮细胞是主要的复制载体。根据2009年的一份报告,该病毒被储存在埃及果蝠(Rousettus aegyptiacus)体内。体液、无保护的性行为、破损或受伤的皮肤以及其他体液是主要的传播途径。潜伏期过后,开始出现寒战、头痛、肌痛和胃痛等症状。对于这种感染没有特殊的药物治疗,只有水合治疗和充分的氧合。以下诊断技术可用于确认诊断:(i)抗体捕获酶联免疫吸附试验(ELISA);ii)抗原捕获ELISA试验;Iii)血清中和试验;iv) RT - PCR检测;V)电子显微镜;或vi)通过细胞培养分离病毒。由于MARV是危险的第4组感染,实验室工作人员必须采取严格的预防措施(RG-4)。
{"title":"Marburg Virus- A Threat During SARS-CoV-2 Era: A Review.","authors":"Sumel Ashique,&nbsp;Vatan Chaudhary,&nbsp;Soumen Pal,&nbsp;Jonee Panwar,&nbsp;Mukesh Kumar,&nbsp;Soumi Pramanik,&nbsp;Abhipsa Sinha,&nbsp;Anagh Mukherjee","doi":"10.2174/1871526523666230228103845","DOIUrl":"https://doi.org/10.2174/1871526523666230228103845","url":null,"abstract":"<p><p>In the German towns of Marburg, Frankfurt, and Belgrade in 1967, this single negativestranded RNA virus was initially discovered. The importation of infected grivet monkeys from Uganda is what caused this virus-related sickness. As a result of the early link between viruses and non-human primates, this virus is frequently referred to as vervet monkey sickness. This virus causes Marburg hemorrhagic fever in humans and non-human primates. Human endothelial cells serve as the primary vehicle for replication. According to a 2009 report, the virus was being stored in Egyptian fruit bats (Rousettus aegyptiacus). Body fluids, unprotected sex, broken or injured skin, and other bodily fluids are the main routes of transmission. After the incubation period, symptoms like chills, headaches, myalgia, and stomach pain start to show up. There is no specific medication for such an infection, only hydration therapy and adequate oxygenation are followed. The following diagnostic techniques can be used to confirm the diagnosis: (i) an antibody-capture enzyme linked immunosorbent assay (ELISA); ii) an antigen capture ELISA test; iii) a serum neutralization test; iv) an RT PCR assay; v) electron microscopy; or vi) virus isolation by cell culture. Because MARV is a risk group 4 infection, laboratory staff must take strict precautions (RG-4).</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 5","pages":"e280223214111"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
HIV/AIDS Curability Study, Different Approaches and Drug Combination. HIV/AIDS的可治愈性研究,不同的治疗方法和药物组合。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230117115826
Da-Yong Lu, Ting-Ren Lu

Aim: HIV infection is currently an incurable disease characterized by life-long drug utility. Its incurable causality and mechanism are still unknown to us.

Methods: To overcome this therapeutic setback, some breakthroughs should be made by utilizing different approaches. How to plan some experimental and clinical novelty for HIV curability is a modern challenge. In this article, new ideas and approaches for global HIV/AIDS therapeutic strategies are proposed and represented by scientific insights.

Results: Pharmaceutical characteristics, herbal medicine, novel drug targets, cutting-edge biotherapy, drug combination, animal modalities, and immune-stimuli for HIV latency, as well as clearance, are highlighted.

Discussion: To elucidate our understanding of curative treatment for HIV/AIDS, many new pathological discoveries, expansion, technical advances, and potential drug targets are constructed. After the discovery of novel pathogenesis and therapeutic evolution, HIV/AIDS therapeutic curability may become achievable and a reality.

Conclusion: Transformation from animal model investigation to widespread therapies for larger volume of human population is a necessity in modern medicine. In this infectious treatment scenario, major breakthroughs in medicine and drug development are anticipated.

目的:HIV感染是目前以终身药物效用为特征的不治之症。其不可治愈的因果关系和机制仍是未知的。方法:为了克服这一治疗挫折,应利用不同的途径取得一些突破。如何为艾滋病的可治愈性策划一些实验和临床创新是一个现代挑战。在本文中,提出了全球艾滋病治疗策略的新思路和新方法,并以科学见解为代表。结果:强调了药物特性,草药,新药物靶点,尖端生物疗法,药物联合,动物模式,HIV潜伏期和清除的免疫刺激。讨论:为了阐明我们对HIV/AIDS治愈性治疗的认识,许多新的病理发现、扩展、技术进步和潜在的药物靶点被构建。随着新的发病机制的发现和治疗方法的发展,HIV/AIDS的治疗治愈可能成为可能和现实。结论:现代医学必须从动物模型研究转向更大规模的广泛治疗。在这种感染治疗情况下,预计医学和药物开发将取得重大突破。
{"title":"HIV/AIDS Curability Study, Different Approaches and Drug Combination.","authors":"Da-Yong Lu,&nbsp;Ting-Ren Lu","doi":"10.2174/1871526523666230117115826","DOIUrl":"https://doi.org/10.2174/1871526523666230117115826","url":null,"abstract":"<p><strong>Aim: </strong>HIV infection is currently an incurable disease characterized by life-long drug utility. Its incurable causality and mechanism are still unknown to us.</p><p><strong>Methods: </strong>To overcome this therapeutic setback, some breakthroughs should be made by utilizing different approaches. How to plan some experimental and clinical novelty for HIV curability is a modern challenge. In this article, new ideas and approaches for global HIV/AIDS therapeutic strategies are proposed and represented by scientific insights.</p><p><strong>Results: </strong>Pharmaceutical characteristics, herbal medicine, novel drug targets, cutting-edge biotherapy, drug combination, animal modalities, and immune-stimuli for HIV latency, as well as clearance, are highlighted.</p><p><strong>Discussion: </strong>To elucidate our understanding of curative treatment for HIV/AIDS, many new pathological discoveries, expansion, technical advances, and potential drug targets are constructed. After the discovery of novel pathogenesis and therapeutic evolution, HIV/AIDS therapeutic curability may become achievable and a reality.</p><p><strong>Conclusion: </strong>Transformation from animal model investigation to widespread therapies for larger volume of human population is a necessity in modern medicine. In this infectious treatment scenario, major breakthroughs in medicine and drug development are anticipated.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 4","pages":"e170123212803"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10145343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hit or Miss: The Dilemma of Specimen Selection for Microbiological Diagnosis of Rhino-Orbital-Cerebral- COVID-Associated Mucormycosis (ROCM-CAM). 命中或错过:鼻-眶-脑-冠状病毒相关毛霉菌病(ROCM-CAM)微生物诊断标本选择的困境。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220816110905
Vidhi Jain, Alisha Aggarwal, Twishi Shrimali, Kirti Vishwakarma, Debaleena Paul, Sarika Prabhakar Kombade, Vidhu Sharma, Kapil Soni, Bikram Choudhary, Amit Goyal, Ankita Chugh, Sarbesh Tiwari, Deepak Kumar Sharma, Ashwini Agarwal, Sanjeev Misra

Background: We diagnosed various cases of rhino-orbital-cerebral- COVID-associated Mucormycosis (ROCM-CAM) during India's second wave of COVID-19. This helped formulate novel suggestions for improving laboratory output, applicable anywhere in the world.

Methods: To diagnose ROCM-CAM by microbiological methods, we used direct microscopy and conventional culture on various clinical samples within the shortest turn-around time.

Design: Prospective single-center observational study.

Participants: Patients with ROCM-CAM.

Results: Of 113 suspected cases of ROCM-CAM during May 2021, direct microscopy and culture could confirm the disease in 87.61% and 44.25% of patients, respectively. The highest pathogen isolation was seen from maxillary bone fragments, FESS-guided biopsy from pterygopalatine fossae, nasal turbinates and nasal mucosal biopsy. Direct microscopy could diagnose the disease in almost 40% of patients within 24 hours and 60% within two days. Conventional cultures yielded Rhizopus spp. (86%) as the commonest fungal pathogen followed by Mucor spp. (12%) within 7 days. Deep tissue biopsies are more useful for rapid diagnosis than superficial specimens. Routine fungal cultures can supplement case detection and help prognosticate survivors.

Conclusion: The management of ROCM is a surgical emergency. The diagnosis of the condition must therefore be prompt and precise. Despite ongoing antifungal therapy, nasal mucosal tissue, FESSguided, and intra-operative tissue biopsies showed the pathogen's highest diagnostic yield. The diagnostic index improved further when multiple (4-5) high-quality specimens were collected. Nasal swabs and crusts, among the most commonly requested specimens worldwide, were found to have an overall low diagnostic potential.

背景:我们在印度第二波COVID-19期间诊断了多例鼻-眶-脑- covid -相关毛霉菌病(ROCM-CAM)。这有助于制定新的建议,以提高实验室产出,适用于世界任何地方。方法:采用微生物学方法诊断ROCM-CAM,在最短的周转时间内对多种临床标本进行直接镜检和常规培养。设计:前瞻性单中心观察性研究。参与者:ROCM-CAM患者。结果:2021年5月113例疑似ROCM-CAM病例中,直接镜检确诊率为87.61%,培养确诊率为44.25%。上颌骨碎片、翼腭窝fess引导活检、鼻鼻甲和鼻黏膜活检中病原菌分离率最高。直接显微镜检查可以在24小时内诊断出近40%的患者,在两天内诊断出60%的患者。常规培养7天内最常见的真菌病原菌为根霉(86%),其次是毛霉(12%)。对于快速诊断,深层组织活检比表面标本更有用。常规真菌培养可以补充病例检测并帮助预测幸存者。结论:ROCM的处理是一种外科急诊。因此,对病情的诊断必须及时准确。尽管持续进行抗真菌治疗,鼻黏膜组织、fess引导和术中组织活检显示病原体的诊断率最高。当采集多个(4-5个)优质标本时,诊断指标进一步提高。鼻拭子和鼻痂是全世界最常要求的标本之一,但总体上诊断潜力较低。
{"title":"Hit or Miss: The Dilemma of Specimen Selection for Microbiological Diagnosis of Rhino-Orbital-Cerebral- COVID-Associated Mucormycosis (ROCM-CAM).","authors":"Vidhi Jain,&nbsp;Alisha Aggarwal,&nbsp;Twishi Shrimali,&nbsp;Kirti Vishwakarma,&nbsp;Debaleena Paul,&nbsp;Sarika Prabhakar Kombade,&nbsp;Vidhu Sharma,&nbsp;Kapil Soni,&nbsp;Bikram Choudhary,&nbsp;Amit Goyal,&nbsp;Ankita Chugh,&nbsp;Sarbesh Tiwari,&nbsp;Deepak Kumar Sharma,&nbsp;Ashwini Agarwal,&nbsp;Sanjeev Misra","doi":"10.2174/1871526522666220816110905","DOIUrl":"https://doi.org/10.2174/1871526522666220816110905","url":null,"abstract":"<p><strong>Background: </strong>We diagnosed various cases of rhino-orbital-cerebral- COVID-associated Mucormycosis (ROCM-CAM) during India's second wave of COVID-19. This helped formulate novel suggestions for improving laboratory output, applicable anywhere in the world.</p><p><strong>Methods: </strong>To diagnose ROCM-CAM by microbiological methods, we used direct microscopy and conventional culture on various clinical samples within the shortest turn-around time.</p><p><strong>Design: </strong>Prospective single-center observational study.</p><p><strong>Participants: </strong>Patients with ROCM-CAM.</p><p><strong>Results: </strong>Of 113 suspected cases of ROCM-CAM during May 2021, direct microscopy and culture could confirm the disease in 87.61% and 44.25% of patients, respectively. The highest pathogen isolation was seen from maxillary bone fragments, FESS-guided biopsy from pterygopalatine fossae, nasal turbinates and nasal mucosal biopsy. Direct microscopy could diagnose the disease in almost 40% of patients within 24 hours and 60% within two days. Conventional cultures yielded Rhizopus spp. (86%) as the commonest fungal pathogen followed by Mucor spp. (12%) within 7 days. Deep tissue biopsies are more useful for rapid diagnosis than superficial specimens. Routine fungal cultures can supplement case detection and help prognosticate survivors.</p><p><strong>Conclusion: </strong>The management of ROCM is a surgical emergency. The diagnosis of the condition must therefore be prompt and precise. Despite ongoing antifungal therapy, nasal mucosal tissue, FESSguided, and intra-operative tissue biopsies showed the pathogen's highest diagnostic yield. The diagnostic index improved further when multiple (4-5) high-quality specimens were collected. Nasal swabs and crusts, among the most commonly requested specimens worldwide, were found to have an overall low diagnostic potential.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 1","pages":"e160822207524"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical Potential of Photodynamic Therapy in Skin Disorder. 光动力治疗皮肤病的临床潜力。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220907113617
Arun Kumar Singh, Rishabha Malviya, Swati Verma
{"title":"Clinical Potential of Photodynamic Therapy in Skin Disorder.","authors":"Arun Kumar Singh,&nbsp;Rishabha Malviya,&nbsp;Swati Verma","doi":"10.2174/1871526522666220907113617","DOIUrl":"https://doi.org/10.2174/1871526522666220907113617","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e070922208600"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10225532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS CoV-2 Omicron (B. 1.1. 529) Recent Updates and Challenges Worldwide. SARS CoV-2基因组(B. 1.1)529)世界范围内的最新情况和挑战。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230324113146
Rina Das, Sherril Yadav, Vishal Sharma, Sumeet Gupta, Anju Goyal, Dinesh Kumar Mehta

The current world is plagued by unpredictability as a result of various COVID-19 variants. The current variants of concern (VOCs) are B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617/B.1.617.2(Delta). WHO classified two variants, delta (B.1.617.2) and omicron (B.1.1.529), as having highly mutable strikes. The WHO predicted that it would be more dangerous than previous variants due to its mutatable capability. The Omicron variant of coronavirus has caused widespread disruption, with countries struggling to manage the massive number of infections. Due to its unique properties, such as protein structure, symptoms, transmission, and epidemiology, this review aims to compare omicron to other variants. Furthermore, we have highlighted vaccines that have been used to combat this pandemic.

当前世界因各种COVID-19变体而受到不可预测性的困扰。目前关注的挥发性有机化合物(VOCs)的变体是B.1.1.7 (Alpha)、B.1.351 (Beta)、P.1 (Gamma)和B.1.617/B.1.617.2(Delta)。世卫组织将delta (B.1.617.2)和omicron (B.1.1.529)这两种变异归为具有高度可变的罢工。世界卫生组织预测,由于具有变异能力,它将比以前的变种更加危险。冠状病毒的欧米克隆变种造成了广泛的破坏,各国正在努力控制大量感染。由于其独特的特性,如蛋白质结构、症状、传播和流行病学,本综述旨在将组粒与其他变异进行比较。此外,我们还强调了用于防治这一流行病的疫苗。
{"title":"SARS CoV-2 Omicron (B. 1.1. 529) Recent Updates and Challenges Worldwide.","authors":"Rina Das,&nbsp;Sherril Yadav,&nbsp;Vishal Sharma,&nbsp;Sumeet Gupta,&nbsp;Anju Goyal,&nbsp;Dinesh Kumar Mehta","doi":"10.2174/1871526523666230324113146","DOIUrl":"https://doi.org/10.2174/1871526523666230324113146","url":null,"abstract":"<p><p>The current world is plagued by unpredictability as a result of various COVID-19 variants. The current variants of concern (VOCs) are B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617/B.1.617.2(Delta). WHO classified two variants, delta (B.1.617.2) and omicron (B.1.1.529), as having highly mutable strikes. The WHO predicted that it would be more dangerous than previous variants due to its mutatable capability. The Omicron variant of coronavirus has caused widespread disruption, with countries struggling to manage the massive number of infections. Due to its unique properties, such as protein structure, symptoms, transmission, and epidemiology, this review aims to compare omicron to other variants. Furthermore, we have highlighted vaccines that have been used to combat this pandemic.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 5","pages":"e240323214950"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10217950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adenovirus Meningoencephalitis and Neurocysticercosis Co-infection: First Case from India. 腺病毒脑膜脑炎和神经囊虫病合并感染:印度首例病例。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230329123428
Anju Dinkar, Jitendra Singh, Bhavya J, Swati Singh, Nilesh Kumar, Kailash Kumar

Background: Adenovirus generally causes upper and lower respiratory tract infections. It is common in children and occasionally in adults. Neurological involvement is rare, which may be mild aseptic meningitis to potentially fatal acute necrotizing encephalopathy. Recently, viruses have been reported increasingly to cause CNS infections. Viral aetiology typically varies with age.

Case presentation: Here, we report an unusual adenovirus meningoencephalitis with a co-infection of neurocysticercosis in an immunocompetent adult patient. An 18-year-old healthy female student was admitted with fever and headache for 11 days and progressive altered behaviour for 5 days, followed by altered sensorium for 3 days. This variable and unusual presentation of adenoviral infection involving CNS provoked diagnostic difficulties, but with the help of advanced diagnostics, especially molecular, exact aetiology was detected. Even with the neurocysticercosis infection in this patient, the outcome was not adversely affected.

Conclusion: This unusual co-infection with a successful outcome is the first case of this type in literature.

背景:腺病毒通常引起上呼吸道和下呼吸道感染。它常见于儿童,偶尔见于成人。很少累及神经系统,可能是轻微的无菌性脑膜炎,也可能是致命的急性坏死性脑病。最近,病毒引起中枢神经系统感染的报道越来越多。病毒的病因通常随年龄而变化。病例介绍:在这里,我们报告一个不寻常的腺病毒脑膜脑炎与神经囊虫病合并感染的免疫功能正常的成人患者。一名18岁健康女学生入院,发热、头痛11天,进行性行为改变5天,随后感觉改变3天。这种涉及中枢神经系统的腺病毒感染的变化和不寻常的表现引起了诊断困难,但在先进诊断的帮助下,特别是分子,准确的病因被检测到。即使该患者感染了神经囊虫病,结果也没有受到不利影响。结论:这种罕见的合并感染的成功结局是文献中第一例此类病例。
{"title":"Adenovirus Meningoencephalitis and Neurocysticercosis Co-infection: First Case from India.","authors":"Anju Dinkar,&nbsp;Jitendra Singh,&nbsp;Bhavya J,&nbsp;Swati Singh,&nbsp;Nilesh Kumar,&nbsp;Kailash Kumar","doi":"10.2174/1871526523666230329123428","DOIUrl":"https://doi.org/10.2174/1871526523666230329123428","url":null,"abstract":"<p><strong>Background: </strong>Adenovirus generally causes upper and lower respiratory tract infections. It is common in children and occasionally in adults. Neurological involvement is rare, which may be mild aseptic meningitis to potentially fatal acute necrotizing encephalopathy. Recently, viruses have been reported increasingly to cause CNS infections. Viral aetiology typically varies with age.</p><p><strong>Case presentation: </strong>Here, we report an unusual adenovirus meningoencephalitis with a co-infection of neurocysticercosis in an immunocompetent adult patient. An 18-year-old healthy female student was admitted with fever and headache for 11 days and progressive altered behaviour for 5 days, followed by altered sensorium for 3 days. This variable and unusual presentation of adenoviral infection involving CNS provoked diagnostic difficulties, but with the help of advanced diagnostics, especially molecular, exact aetiology was detected. Even with the neurocysticercosis infection in this patient, the outcome was not adversely affected.</p><p><strong>Conclusion: </strong>This unusual co-infection with a successful outcome is the first case of this type in literature.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 5","pages":"e290323215132"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10217959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social Avoidance and Emotional Deprivation of Healthcare Providers during the COVID-19 Pandemic. COVID-19大流行期间医疗服务提供者的社会回避和情感剥夺
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526523666230516155643
Esmaeil Mehraeen, Parinaz Paranjkhoo, SeyedAhmad SeyedAlinaghi, Daniel Hackett
{"title":"Social Avoidance and Emotional Deprivation of Healthcare Providers during the COVID-19 Pandemic.","authors":"Esmaeil Mehraeen,&nbsp;Parinaz Paranjkhoo,&nbsp;SeyedAhmad SeyedAlinaghi,&nbsp;Daniel Hackett","doi":"10.2174/1871526523666230516155643","DOIUrl":"https://doi.org/10.2174/1871526523666230516155643","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 6","pages":"e160523216981"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10218101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Toxoplasma gondii Activity of Curcumin: A Systematic Review of Pre-clinical Studies. 姜黄素抗刚地弓形虫活性的临床前研究综述
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.2174/1871526522666220820185637
Hamed Kalani, Pegah Shakib, Roghiyeh Faridnia, Jeffery Ho, Omid Mardanshah, Mehrdad Dolatshah, Asghar Sepahvand, Kourosh Cheraghipour, Masoomeh Zivdaria

Objective: This study has focused on anti-Toxoplasma gondii activity of curcumin.

Methods: In this systematic review, anti-parasitic activity of Curcuma longa on Toxoplasma gondii was assessed. Therefore, several databases, including PubMed, Scopus, Web of Science, Embase and Google Scholar, were searched from 2010 to 2020.

Results: Of the 2200 papers retrieved between 2010 and 2020, six articles were reliable and were scrutinized. In 2 in vitro studies, the most used strain was the RH strain of Toxoplasma gondii, whereas among 4 in vivo studies, RH strain was found in 2 (50%) studies, Me49 strain in 1(25%) study, and RH and Me49 strain in 1 (25%) study. In four in vivo studies, the most used animal model was BALB/c, and Swiss albino was found in 1 study (25%) and Albino rats in 1 study (25%).

Conclusion: Curcumin and nanoparticles formulated with curcumin are new and useful agents for the treatment of parasitic diseases and reduction of drug resistance. The success of this therapeutic approach stems from the specific action of Curcuma longa against parasites and pathogens.

目的:研究姜黄素抗刚地弓形虫的活性。方法:系统评价姜黄对刚地弓形虫的抗寄生活性。因此,从2010年到2020年,我们检索了PubMed、Scopus、Web of Science、Embase和Google Scholar等数据库。结果:在2010 - 2020年间检索到的2200篇论文中,有6篇是可靠的,并经过了审查。在2项体外研究中,使用最多的是弓形虫RH株,而在4项体内研究中,2项(50%)研究中发现了RH株,1项(25%)研究中发现了Me49株,1项(25%)研究中发现了RH和Me49株。在4项体内研究中,使用最多的动物模型是BALB/c, 1项研究(25%)发现瑞士白化(Swiss albino), 1项研究(25%)发现白化大鼠。结论:姜黄素及其纳米颗粒是治疗寄生虫病和降低耐药性的新型有效药物。这种治疗方法的成功源于姜黄对寄生虫和病原体的特殊作用。
{"title":"Anti-<i>Toxoplasma gondii</i> Activity of Curcumin: A Systematic Review of Pre-clinical Studies.","authors":"Hamed Kalani,&nbsp;Pegah Shakib,&nbsp;Roghiyeh Faridnia,&nbsp;Jeffery Ho,&nbsp;Omid Mardanshah,&nbsp;Mehrdad Dolatshah,&nbsp;Asghar Sepahvand,&nbsp;Kourosh Cheraghipour,&nbsp;Masoomeh Zivdaria","doi":"10.2174/1871526522666220820185637","DOIUrl":"https://doi.org/10.2174/1871526522666220820185637","url":null,"abstract":"<p><strong>Objective: </strong>This study has focused on anti-Toxoplasma gondii activity of curcumin.</p><p><strong>Methods: </strong>In this systematic review, anti-parasitic activity of Curcuma longa on Toxoplasma gondii was assessed. Therefore, several databases, including PubMed, Scopus, Web of Science, Embase and Google Scholar, were searched from 2010 to 2020.</p><p><strong>Results: </strong>Of the 2200 papers retrieved between 2010 and 2020, six articles were reliable and were scrutinized. In 2 in vitro studies, the most used strain was the RH strain of Toxoplasma gondii, whereas among 4 in vivo studies, RH strain was found in 2 (50%) studies, Me49 strain in 1(25%) study, and RH and Me49 strain in 1 (25%) study. In four in vivo studies, the most used animal model was BALB/c, and Swiss albino was found in 1 study (25%) and Albino rats in 1 study (25%).</p><p><strong>Conclusion: </strong>Curcumin and nanoparticles formulated with curcumin are new and useful agents for the treatment of parasitic diseases and reduction of drug resistance. The success of this therapeutic approach stems from the specific action of Curcuma longa against parasites and pathogens.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e200822207821"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious disorders drug targets
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1